Fennec Pharmaceuticals Inc. - Common Stock (NQ:FENC)

10.53 +0.18 (+1.74%)

Delayed Quote Updated: 12:59 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fennec Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 Next >

Adherex Technologies Q2 Earnings Call Highlights ↗

August 11, 2026

Adherex Technologies (NASDAQ:FENC), operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year...

Via MarketBeat

Topics Earnings

Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter ↗

May 23, 2026

Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside...

Via MarketBeat

Topics Intellectual Property

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026

From Fennec Pharmaceuticals Inc.

Via GlobeNewswire

Fennec Pharmaceuticals (NASDAQ:FENC) Q1 Beat Overshadowed by Surging Costs ↗

May 14, 2026

Via Chartmill

Fennec Pharmaceuticals (NASDAQ:FENC) Reports Q4 2025 Revenue Growth but Misses Earnings Estimates ↗

March 24, 2026

Via Chartmill

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

Fennec Pharmaceuticals Earnings Preview ↗

August 13, 2025

Via Benzinga

Fennec Pharmaceuticals's Earnings Outlook ↗

March 20, 2024

Via Benzinga

These stocks are moving in today's session ↗

May 14, 2026

Via Chartmill

Fennec (FENC) Q1 2026 Earnings Call Transcript ↗

May 14, 2026

Fennec (FENC) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Adherex Technologies Q1 Earnings Call Highlights ↗

May 14, 2026

Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow...

Via MarketBeat

Topics Earnings

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026

From Fennec Pharmaceuticals Inc.

Via GlobeNewswire

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

May 07, 2026

From Fennec Pharmaceuticals Inc.

Via GlobeNewswire

Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

April 21, 2026

From Fennec Pharmaceuticals Inc.

Via GlobeNewswire

Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year ↗

March 15, 2026

This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.

Via The Motley Fool

Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in Revenue ↗

March 15, 2026

Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets.

Via The Motley Fool

Solas Capital Loads Up On Kyndryl With 407,000 Shares Bought ↗

March 05, 2026

This technology firm delivers IT infrastructure and managed solutions to major enterprises across multiple global industries.

Via The Motley Fool

Topics Artificial Intelligence

Fennec Q2 Sales Jump 33 Percent ↗

August 14, 2025

Via The Motley Fool

Fennec (FENC) Q2 2025 Earnings Call Transcript ↗

August 14, 2025

Via The Motley Fool

Topics Earnings Intellectual Property

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Reports Mixed Q2 2025 Earnings with Revenue Slight Miss and Wider-Than-Expected Loss ↗

August 14, 2025

Fennec Pharmaceuticals reported mixed Q2 2025 results, missing revenue estimates by 0.6% and posting a wider EPS loss. PEDMARK® growth and new accounts drove optimism despite financial...

Via Chartmill

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? ↗

March 10, 2025

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir...

Via Benzinga

Topics Economy Stocks

Earnings Scheduled For March 10, 2025 ↗

March 10, 2025

Via Benzinga

Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗

February 10, 2025

Via Benzinga

FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ↗

August 13, 2024

FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! ↗

July 29, 2024

These dirt cheap stocks under $10 have the potential to rise rapidly and create fortunes for bold investors.

Via InvestorPlace

FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 14, 2024

FENC stock results show that Fennec Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 ↗

March 21, 2024

FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 14, 2024

Via Benzinga

Earnings Scheduled For March 21, 2024 ↗

March 21, 2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.